TY - JOUR
T1 - Molecular and functional studies of retinal degeneration as a clinical presentation of SACS-related disorder
AU - Blumkin, Lubov
AU - Bradshaw, Teisha
AU - Michelson, Marina
AU - Kopler, Tal
AU - Dahari, Dvir
AU - Lerman-Sagie, Tally
AU - Lev, Dorit
AU - Chapple, J. Paul
AU - Leshinsky-Silver, Esther
N1 - Publisher Copyright:
© 2015 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background ARSACS (autosomal-recessive spastic ataxia of Charlevoix-Saguenay) is a neurodegenerative disorder caused by SACS gene mutations and characterized by a triad of symptoms: early-onset cerebellar ataxia, spasticity and peripheral neuropathy. A characteristic retinal nerve fiber hypertrophy has been reported in several individuals with ARSACS. Methods We describe a patient with a unique clinical presentation of ataxia, nystagmus, dysarthria, hearing impairment, and retinal degeneration. Whole-exome-sequencing was performed as well as morphological studies in the patient's fibroblasts. Results A compound heterozygosity for a novel D3269N and N2380K mutations in the SACS gene was found. The parents are carriers. Morphological studies revealed a dramatic decrease in the number of cell mitochondria as well as a difference in mitochondrial network morphology. Conclusions Retinal degeneration has never been reported in ARSACS. Since sacsin is involved in the mitochondrial fusion-fission process, we speculate that defected fission process may be responsible for an impaired mitochondrial function and retinal degeneration. Our patient has a unique clinical presentation of SACS mutations inconsistent with the classic ARSACS triad but also different from the "atypical" presentations described in the literature. Further studies are necessary to clarify the factors that modify the SACS related phenotype.
AB - Background ARSACS (autosomal-recessive spastic ataxia of Charlevoix-Saguenay) is a neurodegenerative disorder caused by SACS gene mutations and characterized by a triad of symptoms: early-onset cerebellar ataxia, spasticity and peripheral neuropathy. A characteristic retinal nerve fiber hypertrophy has been reported in several individuals with ARSACS. Methods We describe a patient with a unique clinical presentation of ataxia, nystagmus, dysarthria, hearing impairment, and retinal degeneration. Whole-exome-sequencing was performed as well as morphological studies in the patient's fibroblasts. Results A compound heterozygosity for a novel D3269N and N2380K mutations in the SACS gene was found. The parents are carriers. Morphological studies revealed a dramatic decrease in the number of cell mitochondria as well as a difference in mitochondrial network morphology. Conclusions Retinal degeneration has never been reported in ARSACS. Since sacsin is involved in the mitochondrial fusion-fission process, we speculate that defected fission process may be responsible for an impaired mitochondrial function and retinal degeneration. Our patient has a unique clinical presentation of SACS mutations inconsistent with the classic ARSACS triad but also different from the "atypical" presentations described in the literature. Further studies are necessary to clarify the factors that modify the SACS related phenotype.
KW - ARSACS
KW - Ataxia
KW - Hearing loss
KW - Night blindness
KW - Retinal degeneration
KW - SACS
UR - http://www.scopus.com/inward/record.url?scp=84931577761&partnerID=8YFLogxK
U2 - 10.1016/j.ejpn.2015.02.005
DO - 10.1016/j.ejpn.2015.02.005
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25819952
AN - SCOPUS:84931577761
SN - 1090-3798
VL - 19
SP - 472
EP - 476
JO - European Journal of Paediatric Neurology
JF - European Journal of Paediatric Neurology
IS - 4
ER -